The American Society for Clinical Oncology (ASCO) has featured an Australian trial of neoadjuvant therapy in melanoma as a part of its 2020 Advance of the Year in cancer. In its annual review, ASCO selected Refinement of Surgical Treatment of Cancer as the 2020 Advance of the Year, saying that studies such as the NeoCombi ...
Australian melanoma research is featured as ASCO cancer advance of the year
By Michael Woodhead
12 Feb 2020